Bruce Ling  LinkedIn Icon

 

Co-founder

Dr. Bruce Ling is a co-founder of HBI Solutions and focuses on analytic solution development, including predictive modeling.

He is a principal investigator in the Department of Surgery at Stanford University School of Medicine, responsible for translational medicine efforts to deliver next-generation diagnostic devices and potential new therapies that clinicians will use for years to come. His computational lab currently focuses on novel statistical learning algorithm innovation, large-scale scientific computing and robust experimental design.

He previously served as research director at Amgen & Tularik Inc. to tap the power of high-throughput biotechnologies and computational innovations to advance their drug discovery programs. As an executive function head, Dr. Ling contributed significantly to pharmaceutical development at Tularik Inc., which was acquired by Amgen for $1.3 billion and gave Amgen access to a trove of potential medications for cancer and inflammatory diseases. Prior to that, he was associate director of research at DoubleTwist Inc., responsible for innovative genomic algorithm development and database architect for its flagship product.

Bruce Ling  LinkedIn Icon

Co-founder

Bruce is a co-founder of HBI Solutions and focuses on analytic solution development, including predictive modeling.

He is a Principal Investigator in the Department of Surgery at Stanford University School of Medicine responsible for the translational medicine efforts to deliver next generation diagnostic devices and potential new therapies that clinicians will use for years to come. His computational lab currently focuses on novel statistical learning algorithm innovation, large scale scientific computing and robust experimental design.

He previously served as Research Director at Amgen & Tularik Inc. to tap the power of high throughput biotechnologies and computational innovations to advance the drug discovery programs. As an executive function head, Dr. Ling contributed significantly to the pharmaceutical development in Tularik Inc., which was acquired by Amgen for $1.3 billion and gave Amgen access to a trove of potential medications for cancer and inflammatory diseases. Prior to that, he was Associate Director of Research at DoubleTwist Inc., responsible for innovative genomic algorithm development and database architect for their flagship product.

Our Expert Staff

The backbone of HBI Solutions is our staff of accomplished researchers, clinicians, PhD data scientists, and expert developers—all equally passionate about our mission to support the delivery of better care at a lower cost.